AstraZeneca Medicines  Medicines AstraZeneca Medicines  Medicines
  • Home
  • Cardiovascular
    • Cardiovascular
    • Brilique (ticagrelor)
      • Brilique (ticagrelor)
      • Product Information
        • Product Information
        • Indications
        • Prescribing BRILIQUE 90mg
        • BRILIQUE 90mg ODT
        • Prescribing BRILIQUE 60mg
        • Administration
        • Warnings and precautions
        • Other adverse events
      • Guidelines
      • Clinical Studies
      • Real World Experience with BRILIQUE from key experts
      • Mode of Action
        • Mode of Action
        • BRILIQUE is not a thienopyridine
        • BRILIQUE works via a dual pathway
      • Resources
      • References
      • Calibre home
      • ACS case studies
        • ACS case studies
        • Dr Hussain Contractor - P2Y12 inhibitors improve ACS survival
      • Hot topics
        • Hot topics
        • Jan Naybour - Cardiac Rehabilitation
        • Dr Yahya Al-Najjar - The high-risk post-myocardial infarction (MI) patient pathway
        • Professor Ahmet Fuat - Long-term management of high-risk post-MI patients
      • Expert opinion
        • Expert opinion
        • Professor Rick Body - Acute Coronary Syndrome (ACS) Diagnosis - The Future
        • Dr Marc Bonaca - Approaches to patient selection for long-term DAPT
      • Meeting calendar
      • Useful links
    • LOKELMA ▼ (sodium zirconium cyclosilicate)
      • LOKELMA ▼ (sodium zirconium cyclosilicate)
      • Product Information
        • Product Information
        • Indications
        • About LOKELMA
        • Administration
        • Dosing
        • Warnings and precautions
      • About Hyperkalaemia
        • About Hyperkalaemia
        • Hyperkalaemia with comorbidities
        • Hyperkalaemia and mortality risk
        • Hyperkalaemia and chronic kidney disease
        • Hyperkalaemia and heart failure
      • Clinical studies
        • Clinical studies
        • HARMONIZE study overview
        • HARMONIZE pivotal trial
        • HARMONIZE extension phase
        • HARMONIZE across patient types
        • 005 Study Overview
        • 005 study
      • References & Resources
      • Prescribing Information
  • Diabetes
  • Oncology
    • Oncology
    • Faslodex (fulvestrant)
    • Lynparza (olaparib)
      • Lynparza (olaparib)
      • About Lynparza (olaparib) in Ovarian Cancer
      • SOLO-1
      • Platinum-Sensitive Relapsed Setting
      • Safety Information
      • Training and Resources
      • References
    • Tagrisso ▼ (osimertinib)
      • Tagrisso ▼ (osimertinib)
      • Prescribing information
        • Prescribing information
        • Indications
        • Dosing
        • Tolerability
        • Warnings and Precautions
        • Prescribing information IRESSA® (gefitinib)
      • Mechanism of action(MOA)
      • First-line TAGRISSO
        • First-line TAGRISSO
        • FLAURA study design
        • Baseline Characteristics
        • Efficacy
      • Second-line TAGRISSO
        • Second-line TAGRISSO
        • The T790M mutation
        • AURA3 study design
        • Baseline characteristics
        • Efficacy
      • References
      • Contact Us
    • Imfinzi ▼ (durvalumab)
      • Imfinzi ▼ (durvalumab)
      • IMFINZI (NSCLC)
        • IMFINZI (NSCLC)
        • About stage III NSCLC
        • MOA
        • Efficacy
        • PD-L1 TESTING
        • SAFETY
        • Dosing
        • Interactive Case Studies
        • Supporting Materials
      • IMFINZI (ES-SCLC)
        • IMFINZI (ES-SCLC)
        • Disease State
        • Efficacy
        • SAFETY
        • DOSING
        • Supporting Materials
    • Zoladex (goserelin)
      • Zoladex (goserelin)
      • Prescribing Information
        • Prescribing Information
        • Indications & Usage
      • Administration
      • Patient information leaflets and materials
    • BRCA Testing
      • BRCA Testing
      • Why to BRCA test in ovarian cancer
      • Types of BRCA gene mutation
      • About tumour BRCA testing
      • Downloadable testing forms
      • Tumour BRCA testing service
      • Tumour BRCA testing service
      • Tumour BRCA testing service
      • References
  • Haematology
  • Respiratory
    • Respiratory
    • Duaklir Genuair ▼ (aclidinium/formoterol fumarate dehydrate)
      • Duaklir Genuair ▼ (aclidinium/formoterol fumarate dehydrate)
      • Prescribing Information
        • Prescribing Information
        • Indication
        • Dosing and administration
        • How to use the Genuair inhaler
        • Special warnings and precautions
      • References
    • Symbicort Asthma (budesonide/formoterol)
      • Symbicort Asthma (budesonide/formoterol)
      • Product information
        • Product information
        • Therapeutic indications & presentation
      • Over-reliance on SABAs
      • Act on SABA over-reliance
      • Meet Sam
      • Symbicort Maintenance and Reliever Therapy
      • The Turbohaler device
      • Prescribing Symbicort
      • Safety and tolerability
      • Resources
      • References
    • Symbicort COPD (budesonide/formoterol) information
      • Symbicort COPD (budesonide/formoterol) information
      • Product information
        • Product information
        • Indication
      • About COPD
      • ICS/LABAs and Symbicort
        • ICS/LABAs and Symbicort
        • Efficacy
        • Capacity of daily living
        • Device choice (Turbohaler vs pMDI)
        • Tolerability
        • Summary of efficacy and device choice
        • Case study
      • Symbicort in COPD
        • Symbicort in COPD
        • How to use the Turbohaler
        • How to use the pMDI
      • COPD guidelines
      • Cost
      • References
      • Home
      • On demand
      • Meetings calendar
  • Supply chain
    • Supply chain
    • Supply of AstraZeneca medicines
    • Supply Requirements Form
    • Our Medicines
    • Supply of Medicines
    • AstraZeneca Customers
    • Contact Supply Chain
    • FAQ
  • Medical Information
  • More Hide
    AstraZeneca Medicines Medicines
    Back to top

    click here

    Jump to Section...

    • Why to BRCA test in ovarian cancer
    • When to BRCA test your ovarian cancer patients
    • The BRCAct tumour testing service
    • Tumour BRCA test request forms
    • Interpreting results
    • FAQs
    • References
    • Lynparza prescribing information
    Report an Adverse Event

    Thank you for visiting the AstraZeneca Medicines website

    This link will take you to a website not owned by AstraZeneca. AstraZeneca provides this link as a service to our site visitors. AstraZeneca are not responsible for the content or privacy / legal policies of any third party websites.

    Do you wish to continue?

    Cancel Continue

    Thank you for visiting the AstraZeneca Medicines website

    This link will take you to a website not owned by AstraZeneca. AstraZeneca provides this link as a service to our site visitors. AstraZeneca are not responsible for the content or privacy / legal policies of any third party websites.

    Do you wish to continue?

    Cancel Continue
     

    Validating...

    Welcome to AstraZeneca Medicines UK

    The content on this website is intended for UK Healthcare Professionals only. The website contains both promotional and non-promotional content.

    I am not a UK Healthcare Professional

    Welcome to the AstraZeneca Medicines Site

    Sorry, your web browser is not supported

    Unfortunately, you are using an unsupported browser. Please use Google Chrome 52.0 or Internet Explorer 11 or later. Apologies for any inconvenience.

    GB-6911 - June 2017

    Cancel

    AstraZeneca Medicines

    This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk. 

    Additional Info


    • Legal Notice and Terms of Use
    • Privacy Notice
    • Cookie Policy
    • Site Map

    Contact AstraZeneca


    • Contact Us
    • Report Adverse Event

    Adverse events should be reported. Reporting forms and information can be found at  www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com or by calling 0800 783 0033.

    © AstraZeneca 2020. All rights reserved. GB-25816 : December 2020
    Back to top